Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24199011 | 0.85 | L3MBTL1 (0.40) | L3MBTL1MAPTGAAALDH1A1 | |
| SCHEMBL24418586 | 0.83 | NPC1 (0.34) | NPC1RAB9AL3MBTL1MAPT | |
| SCHEMBL17586593 | 0.82 | GAA (0.37) | L3MBTL1MAPTGAAPOLBALDH1A1 | |
| SCHEMBL21469472 | 0.77 | NPC1 (0.39) | NPC1RAB9AL3MBTL1MAPTPOLB | |
| SCHEMBL12795882 | 0.75 | ADAM17 (0.44) | NPC1RAB9AL3MBTL1POLB | |
| SCHEMBL24241638 | 0.72 | PIK3CD (0.32) | — | |
| SCHEMBL14031499 | 0.72 | NPC1 (0.36) | NPC1RAB9AL3MBTL1POLB | |
| SCHEMBL14628813 | 0.72 | GAA (0.40) | L3MBTL1MAPTGAAPOLBALDH1A1 | |
| SCHEMBL18522793 | 0.71 | ALDH1A1 (0.33) | MAPTALDH1A1 | |
| SCHEMBL18499723 | 0.70 | NPC1 (0.34) | NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836813-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | GENZYME CORPORATION (US) | 2020-11-17 | — | — | US | disclosed |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | GENZYME CORPORATION | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836813-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | FCGR3B, FCGRT, FCGR2A | NPC1 3399/4885RAB9A 2027/4885L3MBTL1 467/4885 |
| US-20180100010-A1 | FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION | FCGR3B, FCGRT, FCGR2A | NPC1 3399/4885RAB9A 2027/4885L3MBTL1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.